Platelet activation and inhibition in polycythemia vera and essential thrombocythemia

Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
Blood (Impact Factor: 10.45). 01/2013; 121(10). DOI: 10.1182/blood-2012-10-429134
Source: PubMed


Persistently enhanced platelet activation has been characterized in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) and shown to contribute to a higher risk of both arterial and venous thrombotic complications. The incidence of major bleeding complications is also somewhat higher in PV and ET than in the general population. Although its efficacy and safety was assessed in just one relatively small trial in PV, low-dose aspirin is currently recommended in practically all PV and ET patients. While for most patients with a thrombosis history the benefit/risk profile of antiplatelet therapy is likely to be favorable, in those with no such history this balance will depend critically on the level of thrombotic and hemorrhagic risks of the individual patient. Recent evidence for a chemopreventive effect of low-dose aspirin may tilt the balance of benefits and harm in favor of using aspirin more broadly, but the potential for additional benefits needs regulatory scrutiny and novel treatment guidelines. A clear pharmacodynamic rationale and analytical tools are available for a personalized approach to antiplatelet therapy in ET, and an improved regimen of low-dose aspirin therapy should be tested in a properly sized randomized trial.

10 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Therapeutic stratification after the accurate essential thrombocythemia (ET) diagnosis is made based on the medical history (age, previous thrombosis), clinical assessments (cardiovascular [CV] risk factors, comorbidities, systemic diseases), laboratory examinations (leukocytosis, extreme thrombocytosis, anemia) and if available further sophistical analyses (CD34 count, JAK2V617F homozygosity, and mutant allele burden). Areas covered: Current conventional therapeutic tools for reaching those goals are observation, low-dose aspirin, hydroxyurea, anegrelide and interferon alpha. Those treatment modalities are used alone or in combination to get the therapeutic goals in ET patients. The ET literature search was made in PubMed with particular focus on the clinical trials, recommendations, guidelines and expert opinions. Expert opinion: The most important step for the therapeutic decision of ET in the clinic is the risk assessments. Clinical decision making starts with the detection of the age and the prior thrombosis history of the ET patient. Treatment goals in ET are to avoid thrombosis and bleeding, to treat ET-related symptoms, improve quality of life and to minimize risk of malignant transformation and/or post-ET myelofibrosis.
    Expert Opinion on Pharmacotherapy 05/2013; 14(11). DOI:10.1517/14656566.2013.799140 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dickkopf-3 (Dkk3) has been proposed as tumor suppressor gene and a marker for tumor blood vessels and has pro-angiogenic properties. Dkk3 is expressed in platelets and megakaryocytes from healthy controls and patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN). The aim of this study is, to find out whether patients with MPN have higher Dkk3 serum levels than normal controls. We analyzed Dkk3 serum levels with ELISA in patients with newly diagnosed and untreated MPN, including 10 essential thrombocythemia (ET), 10 polycythemia vera (PV), 10 primary meylofibrosis (PMF) and 10 healthy blood donors and correlated these findings with biological and clinical key data and the JAK2-V617F status. Dkk3 levels were corrected to platelet count, Dkk3c, as patients with MPN have higher platelet counts than controls. As expected, patients with MPN have higher platelet counts than normal controls. Dkk3 serum levels of patients with MPN (5.4±6.1ng/ml) showed no significant difference compared to normal controls (4.4±3.8ng/ml). Regarding Dkk3c, a significant difference to controls was found in PV (8.5±8.7ng/ml; p=0.04), but not in ET and PMF (5.7±3.8ng/ml; p=0.07 and 2.7±3.6ng/ml; p=0.9; respectively. Dkk3c correlated with the JAK2-V617F mutational burden (p=0.014, Rho=0.445). Dkk3 levels corrected to platelet count showed higher levels in PV than normal controls. Elevated Dkk3c level could possibly correlate to platelet activation in PV patients and increased Dkk3 release. Whether this remains a surrogate marker of platelet release or it contributes to the thrombophilic state through its pro-angiogenic properties remains to be shown.
    Thrombosis Research 11/2013; 133(2). DOI:10.1016/j.thromres.2013.11.003 · 2.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Essential thrombocythaemia (ET) is characterised by enhanced platelet generation and thrombosis. Once daily (od) aspirin incompletely inhibits platelet thromboxane (TX)A2 production in ET. A twice daily (bid) dosing is necessary to fully inhibit TXA2. Whether this dosing regimen affects in vivo prostacyclin (PGI2) biosynthesis is unknown. PGI2 biosynthesis was characterised in 50 ET patients on enteric-coated (EC) aspirin 100 mg od, by measuring its urinary metabolite, 2,3-dinor-6-keto-PGF1α (PGI-M). Moreover, in a crossover study 22 patients poorly responsive to standard aspirin based on serum TXB2 levels (≥4 ng/ml) were randomised to different seven-day aspirin regimens: EC aspirin 100 mg od, 100 mg bid, 200 mg od, or plain aspirin 100 mg od. PGI-M measured 24 hours after the last aspirin intake (EC, 100 mg od) was similar in patients and healthy subjects both on (n=10) and off (n=30) aspirin. PGI-M was unrelated to in vivo TXA2 biosynthesis, and not affected by EC aspirin 100 mg bid or 200 mg od as compared to EC 100 mg od. PGI2 biosynthesis in aspirin-treated ET patients appears unrelated to TXA2 biosynthesis, and not affected by an improved aspirin regimen, demonstrating its vascular safety for future trials.
    Thrombosis and Haemostasis 03/2014; 112(1). DOI:10.1160/TH13-10-0844 · 4.98 Impact Factor
Show more